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INTRODUCTION
The coronavirus disease 2019 (COVID-19) spread rapidly 
around the world, causing the World Health Organization 
to declare a global pandemic on March 11, 2020. As of 
April 30, 2020, COVID-19 was confirmed in over 100 coun-
tries, causing more than 3,000,000 confirmed cases and 
223,193 deaths globally [1]. Although the case fatality rate 
is low in the general population, it is higher among patients 
with advanced age or underlying comorbidities [2]. In the 
absence of a vaccine or effective treatment, questions 
arise on the risk of COVID-19 to patients with end-stage 
organ disease that are awaiting transplant surgery [3,4]. 
Organ transplantation saves thousands of lives; howev-
er, transplant recipients, because of immunosuppression 
and underlying medical conditions, might be at higher risk 
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of contracting COVID-19 and developing severe illness [5]. 
As the pandemic worsens around the world, procurements 
of organs from deceased donors have decreased, and 
transplantations from living donors have been postponed 
to preserve medical resources for COVID-19 and to avoid 
nosocomial transmission [6,7]. 
During the COVID-19 pandemic, decision-making about 
whether to proceed with organ transplantation is challeng-
ing. Although transplantation societies have proposed 
interim recommendations, little is known about the safety 
and feasibility of organ transplantation under enhanced 
infection prevention measures during the COVID-19 out-
break [5]. We report on the measures we have taken to 
reduce the transmission of COVID-19 and our experiences 
with living donor and deceased donor transplants in the 
initial phase of the COVID-19 pandemic in South Korea.
METHODS
All study procedures were conducted in accordance with 
the Declaration of Helsinki and were approved by the In-
stitutional Review Board of Severance Hospital (IRB No. 
2020-0500-001). Requirement for informed consent was 
waived by the Institutional Review Board because of the 
study’s retrospective design. All living donations were 
voluntary, and all donors underwent evaluation by trans-
plant surgeons, hepatologists, nephrologists, and clinical 
psychologists. All deceased donors were brain dead. No 
donor organs were obtained from executed prisoners or 
other institutionalized persons.
Data Collection 
In this retrospective study, we reviewed consecutive liver 
transplantations and kidney transplantations performed at 
the Severance Hospital Transplant Center from January 20, 
2020 to April 30, 2020. We also analyzed transplantations 
performed at our hospital during the same period in 2019 
(January 20 to April 30). Severance Hospital is a 2,400-
bed, university-affiliated tertiary care hospital in Seoul, 
located about 240 km (150 miles) from the epicenter of 
the COVID-19 pandemic in South Korea (Daegu and North 
Gyeongsang province). The Severance Hospital Transplant 
Center, one of the largest Korean centers for organ trans-
plantation, performs approximately 180 kidney transplants 
and 120 liver transplants annually. We reviewed electronic 
medical records, laboratory findings, and radiological ex-
aminations of all recipients and donors. We also analyzed 
data from the Korean Network for Organ Sharing (KONOS) 
database, which contains national data on organ dona-
tions and transplantations [8,9].
Infection Prevention Measures
We established a makeshift dedicated triage for patients 
with fever or respiratory symptoms to prevent COVID-19 
exposure to patients and healthcare providers. All patients 
and visitors to the hospital were screened using a standard 
questionnaire and thermal imaging cameras. We adopted 
universal face masking policy for healthcare workers in all 
clinical settings. In addition, healthcare workers who come 
into direct or indirect contact with patients with confirmed 
COVID-19 underwent testing for the disease subsequently.
Preoperative patients were screened for COVID-19 
using real time reverse transcription polymerase chain re-
action (RT-PCR) of nasopharyngeal swabs in accordance 
with institutional guidelines. As the situation changed, 
testing criteria for COVID-19 in preoperative patients were 
modified accordingly (Fig. 1). Initially, we adopted preoper-
ative COVID-19 testing for patients with respiratory symp-
toms (February 4; 16 confirmed cases in South Korea), fol-
lowed by testing of patients who had recently traveled to 
or stayed in high risk countries (February 6; 23 confirmed 
cases in South Korea), patients from the South Korean 
epicenter region of Daegu and North Gyeongsang prov-
ince (February 24; 763 confirmed cases in South Korea), 
and immunocompromised patients (February 27; 1,595 
HIGHLIGHTS
• We describe our experiences regarding the continuation 
of living and deceased donor transplantation during the 
initial phase of the coronavirus disease 2019 (COVID-19) 
outbreak.
• We also analyzed national transplant activities using 
Korean Network for Organ Sharing (KONOS) database.
• Transplantation activities with living and deceased 
donors remained stable during the COVID-19 outbreak 
and no transplant recipients in our center contracted 
COVID-19.
• Our early experiences suggest that organ transplanta-
tion is feasible during the COVID-19 pandemic under ap-
propriate infection prevention measures and extensive 
testing.
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confirmed cases in South Korea). Currently, all donors and 
recipients are screened for COVID-19 regardless of symp-
toms in accordance with the Korean Society for Transplan-
tation recommendation (released on March 13, 2020) [10]. 
In addition, surgeries for patients from the epicenter 
region were scheduled after all other surgeries were per-
formed in a negative pressure operating theater. After sur-
gery, patients from the epicenter recovered from anesthe-
sia in the operating theater instead of the postanesthesia 
care unit and were then sent directly back to the ward to 
minimize contact with other patients.
Immunosuppressive Regimen
Immunosuppression was performed as described previ-
ously [11]. Most patients that received living donor trans-
plants received induction therapy with basiliximab (20 mg 
on days 0 and 4 posttransplant). We used anti-thymocyte 
globulin (ATG) for induction in human leukocyte antigen 
(HLA)-incompatible kidney transplantation and deceased 
donor kidney transplantation (1.5 mg/kg per day for 4 
days). The maintenance regimen consisted of tacrolimus, 
corticosteroid, and mycophenolate mofetil (MMF). Initial 
tacrolimus was administered orally at 0.1 mg/kg twice dai-
ly. The dose of tacrolimus was adjusted to maintain serum 
levels at 5–10 ng/mL during the first postoperative month 
and at 5–7 ng/mL thereafter. MMF was started at 1.0–1.5 
g/day and subsequently adjusted to minimize adverse 
events such as leukopenia or gastrointestinal trouble. 
All ABO-incompatible transplantations and HLA-incom-
patible kidney transplantations were performed according 
to the desensitization protocol, as previously described 
[11,12]. Rituximab was administered within 2 weeks before 
transplantation. Plasmapheresis was performed until the 
target antibody titer was achieved (immunoglobulin G titer 
≤1:32 in ABO-incompatible transplantation, conversion of a 
positive crossmatch to negative).
Prophylaxis Protocol 
All patients received trimethoprim-sulfamethoxazole as 
Pneumocystis jirovecii pneumonia prophylaxis for a mini-
mum of 3 months. Fungal prophylaxis consisted of 4 mL 
oral nystatin administered four times daily for 12 months. 
Prophylactic ganciclovir or valganciclovir for cytomega-
lovirus (CMV) prophylaxis was used in high risk patients 
(donor seropositive, recipient seronegative, or use of ATG 
induction). A preemptive approach for prevention of CMV 
infection was used in other patients.
Statistical Analysis
Demographic information was summarized using frequen-
cy counts (percentage) or medians (interquartile range), 
depending on the data type. The chi-square test with Fish-
er’s exact test was used to compare categorical variables. 
The Kruskal-Wallis test was used to compare continuous 
variables. The analysis was performed using IBM SPSS 
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Fig. 1. Preoperative coronavirus disease 
2019 (COVID-19) testing criteria during the 
outbreak. ICU, intensive care unit.
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transplantations were performed (58 kidney, 35 liver, and 
1 simultaneous liver-kidney) compared to 84 in 2019 (48 
kidney, and 36 liver). The proportion of living-donor trans-
plantations was not significantly different between the 2 
years.
Baseline Characteristics 
The baseline characteristics of the liver transplant recip-
ients are shown in Table 1. There were no significant dif-
ferences between the COVID-19 period and the same time 
period in the previous year in terms of patient age, sex, and 
model for end-stage liver score. In both periods, alcoholic 
liver disease and hepatitis B were the two most common 
etiologies. A total of 22 patients had hepatocellular car-
cinoma at the time of liver transplant, and 19 underwent 
pretransplant locoregional treatment. The proportion of 
ABO-incompatible liver transplants was not significantly 
different between two periods (22.2% in 2020 vs. 16.7% in 
2019).
A total of 58 patients underwent kidney transplantation 
during the COVID-19 outbreak. The median age of those 
patients was 51 years, and 48.3% were female. Forty-two 
(72.4%) of the patients that received kidney transplants 
during the COVID-19 outbreak had living donors, and 17 
(29.3%) underwent desensitization treatment prior to 
transplantation (9 ABO-incompatible and 8 HLA-incom-
patible). The baseline characteristics of the kidney trans-
plant patients are summarized in Table 2. There were no 
significant differences between the COVID-19 period and 
the same time period in the previous year in terms of age, 
sex, and diabetes. The use of ATG induction was more 
common in 2020 than in 2019, but the difference was not 
statistically significant (41.4% in 2020 vs. 27.1% in 2019, 
P=0.124).
COVID-19 Test
As of April 30, more than 620,000 individuals were tested 
for COVID-19 in South Korea (population of 51 million). 
A total of 7,550 patients underwent COVID-19 testing by 
real-time RT-PCR according to institutional guidelines 
at Severance Hospital. Among the patients undergoing 
transplantation, 50 recipients and 46 donors underwent 
COVID-19 testing prior to transplantation. During the study 
period, 909 healthcare workers were tested, and all were 
negative for COVID-19.
Postoperative Courses
The postoperative courses are summarized in Table 3. No 
incidence of COVID-19 infection occurred during the study 
period. All liver transplant recipients received care in the 
intensive care unit (ICU) after transplantation. The median 
length of stay in the ICU and duration of ventilator care 
Table 1. Baseline characteristics of LT patients
Variable LT in 2019 (n=36) LT in 2020 (n=36a)) P-value
Age 53.0 (38.8–61.8) 54.5 (45.3–62.8) 0.813
  Elderly (≥60 yr) 12 (33.3) 11 (30.6) 0.800
Female sex 14 (38.9) 12 (33.3) 0.624
Original disease 0.439
  Hepatitis B virus 12 (33.3) 14 (38.9)
  Hepatitis C virus 0 3 (8.3)
  Alcoholic liver disease 12 (33.3) 10 (27.8)
  Biliary disease 5 (13.9) 2 (5.6)
  Others 7 (19.4) 7 (19.4)
Hepatocellular carcinoma 10 (27.8) 12 (33.3) 0.609
  Pretransplant loco-
regional treatment
9/10 (90.0) 10/12 (83.3)
MELD score 14.0 (10.8–28.3) 18.0 (11.8–32.3) 0.988
Diabetes 13 (33.3) 13 (33.3) >0.999
Deceased donor 7 (19.4) 10 (27.8) 0.405
ABO-incompatible LT 6 (16.7) 8 (22.2) 0.551
Values are presented as median (interquartile range) or number (%). 
LT, liver transplantation; MELD, model for end-stage liver disease.
a)One simultaneous liver-kidney transplant case was classified to LT.
Table 2. Baseline characteristics of KT patients
Variable KT in 2019 (n=48) KT in 2020 (n=58) P-value
Age 52.5 (41.3–58.0) 51.0 (45.3–60.0) 0.845
  Elderly (≥60 yr) 10 (20.8) 17 (29.3) 0.319
Female sex 18 (37.5) 28 (48.3) 0.265
Number of HLA mismatch 3.0 (2.0–4.0) 2.5 (1.0–4.0) 0.281
Retransplant  5 (10.4) 5 (8.6) 0.753
Diabetes 16 (33.3) 21 (36.2) 0.757
Deceased donor  9 (18.8) 16 (27.6) 0.286
Desensitization 16 (33.3) 17 (29.3) 0.656
  ABO-incompatible KT 10 9
  HLA-incompatible KTa) 6 8
Induction 0.124
  Basiliximab 35 (72.9) 34 (58.6)
  Anti-thymocyte globulin 13 (27.1) 24 (41.4)
Values are presented as median (interquartile range) or number (%).
KT, kidney transplantation; HLA, human leukocyte antigen.
a)Five patient underwent both HLA- and ABO-incompatible kidney trans-
plant was classified to HLA-incompatible kidney transplant.
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after liver transplantation were not significantly different 
between the COVID-19 period and the same time period 
in the previous year. In addition, the proportion of patients 
who received postoperative continuous renal replacement 
therapy was similar between the two time periods. Post-
operative courses in kidney transplant recipients were not 
significantly different between the two time periods.
Organ Donation and Transplant Activities in Korea
We compared the organ donation and transplant activities 
from January 2020 to April 2020 with those during the 
same time period in the previous year (Table 4). According 
to the KONOS database, a total of 162 deceased donors 
were used in 2020 compared to 152 in 2019 [8]. Transplant 
activities were stable between the two time periods for 
both living donor and deceased donor transplantations [9]. 
In 2020, 1,409 organ transplantations were performed (543 
liver, 774 kidney, 53 heart, and 39 lung) compared to 1,389 
in 2019 (515 liver, 757 kidney, 66 heart, and 51 lung). The 
proportion of living donor transplantations was not signifi-
cantly different between the two time periods.
DISCUSSION
Since the first imported case of COVID-19 was docu-
mented on January 20, 2020, South Korea has carried out 
extensive virus testing and contact tracing [13-15]. In co-
operation with efforts at the national level, our institution 
put stringent measures into place to prevent COVID-19 
transmission. As the situation continues to change rapidly, 
infection control measures for patients undergoing organ 
transplantation have been modified accordingly. Thanks to 
those efforts, we were able to maintain both living donor 
transplantation and deceased donor transplantation for 
our patients. To date, we have not had any instances of 
COVID-19 infection among our patients.
As the outbreak grew to a pandemic, many healthcare 
providers raised the concern that organ transplant recip-
ients might be at higher risk of developing severe illness 
caused by COVID-19 [5]. In prior outbreaks of respiratory 
viruses, organ transplant recipients demonstrated greater 
susceptibility to infection, greater disease severity, and 
prolonged shedding of virus compared with the general 
population [16,17]. However, there are limited data on 
COVID-19 in organ transplant recipients [18]. Although 
organ transplant recipients might be more susceptible to 
COVID-19 infection, it is uncertain whether immunosup-
pression alters the clinical features and disease severity of 
COVID-19. According to data collected so far, the clinical 
features of COVID-19 among transplant recipients are as 
heterogeneous as they are in the general population [19]. 
Furthermore, there are some preliminary reports that the 
reduced immune response due to immunosuppression 
might have a protective effect against severe COVID-19 
symptoms [20,21]. 
Another concern for organ transplantation during the 
COVID-19 crisis is a lack of medical resources [22]. Health-
care providers are under increasing pressure to provide 
care only in the most urgent cases in order to preserve re-
sources for the COVID-19 response [23]. A lack of ICU beds 
and ventilators might not only affect care for transplant 
recipients but also organ procurements from deceased do-
nors [6]. In the face of unprecedented challenges posed by 
Table 3. Postoperative courses after transplantation
Variable 2019 2020 P-value
Liver transplant (n=36) (n=36)
  Length of ICU stay after transplant 3 (2–7) 3 (2–4) 0.948
  Length of ventilator care 2 (1–5) 1 (1–3) 0.227
Continuous renal replacement therapy 8 (22.2) 10 (27.8) 0.586
Kidney transplant (n=48) (n=58)
  ICU care after transplant 2 (4.2) 1 (1.7) 0.589
  Delayed graft function 3 (6.3) 7 (12.1) 0.343
Values are presented as median (interquartile range) or number (%).
ICU, intensive care unit.
Table 4. Overall organ transplant activities in South Korea




Deceased donor 152 162 +6.6
  Elderly (≥60 yr) 38 (25.0) 53 (32.7) +39.5
Overall transplant 1,389 1,409 +1.4
Liver transplant 515 543 +5.4
  Living donor 385 (74.8) 407 (75.0) +5.7
  Deceased donor 130 (25.2) 136 (25.0) +4.4
Kidney transplant 757 774 +2.2
  Living donor 493 (65.1) 473 (61.1) –4.1
  Deceased donor 264 (34.9) 301 (38.9) +14.0
Heart transplant 66 53 –19.7
Lung transplant 51 39 –23.5
Values are presented as number (%).
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COVID-19, some decrease in transplant activities is inevi-
table [7,24]. Unfortunately, the pandemic will not disappear 
soon, and there is potential for a second wave of COVID-19 
[25]. It is difficult to know when transplant activities will be 
able to return safely to previous levels. Therefore, trans-
plant programs have to take measures to continue per-
forming organ transplantations with appropriate infection 
control measures based on the local environment [5,6]. 
During this unprecedented crisis, performing organ trans-
plants is a demanding work. We greatly appreciate the ef-
forts of all medical staffs who are working tirelessly during 
this outbreak. Our experiences provide insights on how to 
recover after the peak of the pandemic. It is important to 
note that infection control measures should be modified 
accordingly as the situation continues to evolve.
Although transplantations are categorized as Tier 3b 
(“do not postpone”) in the Centers for Medicare and Med-
icaid Services recommendations for limiting nonessential 
elective surgeries, elective living donor transplantations 
have been postponed in transplant centers around the 
world [6,7,24]. Although living donor transplantations 
might be on an “elective” schedule, they cannot be con-
sidered elective for many patients with end-stage organ 
disease. The need for a living donor liver transplant can 
be life-threatening if it is not met within a reasonable time 
frame. For patients in need of a kidney transplant, it is un-
safe to delay living donor transplantation because of the 
need for those patients to regularly visit dialysis facilities, 
where they may not be able to practice safe social dis-
tancing [26]. Because it is unclear how long the COVID-19 
pandemic will continue, postponement of living donor 
transplantation might be devastating for patients with 
end-stage organ disease. Therefore, healthcare providers 
should carefully weigh the risks and benefits of postpon-
ing living donor transplantation, even under the dire cir-
cumstances of COVID-19.
Although the impact of COVID-19 is resonating across 
the world, many aspects of COVID-19 remain unknown. 
For example, we still do not know the true prevalence, 
transmission rate, and fatality rate [27]. In addition, we 
do not know the risk of donor-derived transmission of 
COVID-19, nor do we fully understand the immune re-
sponse to COVID-19 or how long the immunity lasts [28]. 
Facing up to the uncertainties of COVID-19, best effort to 
overcome these uncertainties is massive test [29,30]. We 
acknowledge the limited accuracy of real-time RT-PCR and 
the risks of false negative results. In addition, widespread 
real-time RT-PCR testing will produce many true-negative 
results and might therefore seem to be wasteful during 
times of constrained resources [29]. Despite those cave-
ats, extensive testing can reduce nosocomial transmission 
and protect healthcare providers as well as vulnerable pa-
tients from COVID-19. In our experience, ambitious testing 
has allowed us to maintain the very best care for patients 
with end-stage organ disease during the COVID-19 out-
break.
Our study has some limitations. First, it is mostly based 
on a small number of patients from a single center, al-
though we did investigate the overall transplant activities 
in South Korea. Second, no patients with COVID-19 have 
undergone transplantation in our institution. 
The COVID-19 pandemic has impacted healthcare 
systems around the globe. In the face of the COVID-19 
pandemic, we acknowledge the necessity of careful re-
source allocation. In our experience, the maintenance 
of transplant activities during the COVID-19 pandemic 
has required more efforts and resources than what were 
required in the past for the same activities. Despite the 
heightened resource consumption due to the COVID-19 
pandemic, we must continue to try to provide the best 
care for our patients. In the absence of a vaccine or ef-
fective treatment, stringent infection control measures 
and continued collaboration among transplant societies 
are required to get through the crisis. A systemic support 
from government is also needed to sustain lifesaving or-
gan transplants programs. Our early experiences suggest 
that organ transplantation is feasible under appropriate 
infection prevention measures. At this time, appropriate 
infection prevention measures and extensive testing are 
essential strategies for the maintenance of transplant ac-
tivities for our patients.
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